drugset / Trial / NCT06902246
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Timeline
- Start
- 2026-08-01
- Primary completion
- 2031-08-01
- Completion
- 2031-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Regorafenib | Small molecule | 160 mg | Oral |